For years, ex parte reexamination has lived in the shadow of post-grant review. But as PTAB practice evolves and litigation strategies adapt, its utility is becoming harder to ignore. In the right case, it can function not as a blunt instrument, but as a precision tool—quietly reshaping risk, leverage, and outcomes in parallel litigation.